• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a novel anti-cancer drug for metastatic bladder cancer by targeting energy metabolism

Research Project

Project/Area Number 19K09687
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionShiga University of Medical Science

Principal Investigator

Kim Chul Jang  滋賀医科大学, 医学部, 非常勤講師 (10204968)

Co-Investigator(Kenkyū-buntansha) 井上 寛一  滋賀医科大学, 医学部, 非常勤講師 (30176440)
Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords膀胱癌 / ワールブルグ効果 / ピルビン酸脱水素酵素キナーゼ4 / クリプトタンシノン / 上皮間葉転換 / βカテニン / ピルビン酸脱水素酵素キナーゼ4 / 抗がん剤 / エネルギー代謝
Outline of Research at the Start

癌細胞では、好気的環境下でも解糖系によるエネルギー産生が優位となるグルコース代謝のシフト(ワールブルグ効果)が生じている。解糖系の制御の標的として、ピルピン酸からアセチルCoAへの反応を抑制して解糖系を亢進するピルビン酸脱水素酵素キナーゼ4(PDK4)に着目した。本申請では、このPDK4を分子標的とする新しい低分子化合物を用いて、ワールブルグ効果を抑制することによる抗腫瘍活性および転移浸潤抑制活性をヒト膀胱癌のin vitro培養細胞系 およびin vivoのマウス腫瘍モデル実験系を用いて解析し、既存の抗がん剤と異なる代謝を標的とした薬剤による新たな膀胱癌治療法を開発する。

Outline of Final Research Achievements

A majority of cancer cells preferentially metabolize glucose through glycolysis, even under aerobic conditions (Warburg effect), which is a primary metabolic hallmark of cancer cells. Pyruvate dehydrogenase kinase 4 (PDK4) is a key molecule, which via decarboxylation, regulates the oxidative metabolism of pyruvate into acetyl-CoA. Cryptotanshinone (CPT), which is obtained from the traditional Chinese herb danshen, effectively inhibited PDK4 activity at low concentrations to suppress the three dimensional (3D)-spheroid formation and epithelial-mesenchymal transition (EMT) in human bladder cancer cells via β-catenin/N-cadherin pathway. CPT could be a potential treatment option for intractable bladder cancer.

Academic Significance and Societal Importance of the Research Achievements

膀胱癌は、10番目に発生が多い癌であり、浸潤性膀胱癌となった場合には、抗癌剤による治療と根治的膀胱全摘除術による標準治療を行っても満足できる治療結果は得られていない。また、一旦転移癌になると5年生存率は5%以下で、ここ30年間治療結果の改善が見られていない難治性の癌である。今回治療の新しいアプローチとして、癌細胞のエネルギー代謝に注目し、解糖系を抑えることにより癌の上皮間葉転換を抑え、細胞浸潤能を抑制できることを示した。用いた薬剤も漢方の有効成分であるクリプトタンシノンであり、癌治療の新しいアプローチの可能性を示すことができたと考えている。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (12 results)

All 2022 2021 2020 2019

All Journal Article (5 results) (of which Peer Reviewed: 5 results,  Open Access: 2 results) Presentation (7 results)

  • [Journal Article] Application of the indocyanine green fluorescence imaging method in laparoscopic resection of a solitary retroperitoneal metastasis of renal cell carcinoma: A case report.2022

    • Author(s)
      Kim CJ, Nishida M, Hanada E, Kageyama S, Narita M, Kawauchi A
    • Journal Title

      Asian J Endosc Surg

      Volume: 15 Issue: 1 Pages: 172-175

    • DOI

      10.1111/ases.12945

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Cryptotanshinone, a novel pyruvate dehydrogenase kinase 4 inhibitor, suppresses cell invasiveness in bladder cancer cells via the mTOR/β-catenin/N-cadherin axis.2021

    • Author(s)
      Chul Jang Kim, Tokio Terado, Yukihiro Tambe, Ken-ichi Mukaisho, Susumu Kageyama, Akihiro Kawauchi, Hirokazu Inoue
    • Journal Title

      International Journal of Oncology

      Volume: 59 Issue: 1 Pages: 40-51

    • DOI

      10.3892/ijo.2021.5220

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.2021

    • Author(s)
      Okinaka Y, Kageyama S, Nishizawa K, Yoshida T, Ishitoya S, Shichiri Y, Kim CJ, Iwata T, Yokokawa R, Arai Y, Nishikawa Z, Soga H, Ushida H, Sakano Y, Naya Y, Yoshida T, Narita M, Kawauchi A
    • Journal Title

      Prostate

      Volume: 81 Issue: 15 Pages: 1172-1178

    • DOI

      10.1002/pros.24212

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Single short retention instillation of pirarubicin prevents intravesical recurrence of low-risk non muscle invasive bladder cancer2021

    • Author(s)
      Susumu Kageyama, koki Maeda, Shigehisa Kubota, Tetsuya Yoshida, Takashi Osafune, Yutaka Arai, Hiroki Soga, Zenkai Nishikawa, Yuji Sano, Keita Takimoto, Chul Jang Kim, Tokuhiro Chano, Akihiro Kawauchi
    • Journal Title

      in vivo

      Volume: 35 Issue: 2 Pages: 1141-1145

    • DOI

      10.21873/invivo.12360

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer.2019

    • Author(s)
      Tambe, Y., Terado, T., Kim, C. J., Mukaisho, K., Yoshida, S., Sugihara, H., Tanaka, H., Chida, J., Kido, H., Yamaji, K., Yamamoto, T., Nakano, H., Omura, S. and Inoue, H.
    • Journal Title

      Molecular Carinogenesis 58, 1726-1737, 2019

      Volume: 58 Issue: 10 Pages: 1726-1737

    • DOI

      10.1002/mc.23045

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Presentation] A PDK4 inhibitor, cryptotanshinone, inhibits lipid metabolism to suppress tumorigenesis of KRAS-activated cancer cells.2021

    • Author(s)
      Terado T, Tambe Y, Kim CJ, Tanaka H, Inoue H
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Cryptotanshinone, a novel PDK4 inhibitor, suppresses cell invasiveness in bladder cancer cells via β-catenin/N-cadherin.2021

    • Author(s)
      Kim CJ, Terado T, Tambe Y, Mukaisho KI, Kageyama S, Kawauchi A, Inoue H
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 新規ピルビン酸脱水素酵素キナーゼ4(PDK4)阻害剤クリプトタンシノンのβカテニンを介したヒト膀胱癌細胞での細胞浸潤抑制作用2021

    • Author(s)
      金 哲將、寺戸勅雄、旦部幸博、井上寛一、河内明宏
    • Organizer
      第109回日本泌尿器科学会総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Cryptotanshinone, a PDK4 inhibitor, suppresses invasion and metastasis in human bladder and pancreatic cancers2020

    • Author(s)
      Chul Jang Kim, Tokio Terado, Yukihiro Tambe, Ken-ichi Mukaisho, Susumu Kageyama, Akihiro Kawauchi, Hirokazu Inoue
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Research-status Report
  • [Presentation] A novel PDK4 inhibitor inhibits glutamine metabolism to suppress tumorigenesis of KRAS-activated cancer cells.2020

    • Author(s)
      Tokio Terado, Yukihiro Tambe, Chul Jang Kim, Hiroyuki Tanaka, Ken-ichi Mukaisho, Hiroyuki Sugihara, Hirokazu Inoue
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Research-status Report
  • [Presentation] 膵臓癌と膀胱癌における新規PDK4阻害剤による浸潤転移の抑制2019

    • Author(s)
      金 哲將, 寺戸勅雄, 旦部幸博, 河内明宏, 向所賢一, 杉原洋行, 井上寛一
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 新規PDK4阻害剤cryptotanshinoneはPI3K/Akt経路を介してKRAS活性型癌細胞の癌化を抑制する2019

    • Author(s)
      旦部幸博, 寺戸勅雄, 金 哲將, 中野洋文, 向所賢一, 杉原洋行, 井上寛一
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Research-status Report

URL: 

Published: 2019-04-18   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi